# Neoantigen Targeted Therapies Market 2030

**Authors:** wilsonstella522

---

Advances
in bioinformatics and genomic data analysis have enabled the identification of
cancer antigens that are generally overlooked during immune surveillance; these
neoantigens have been shown to possess substantial therapeutic potential

Roots
Analysis is pleased to announce the publication of its recent study, titled, “[**Neoantigen Targeted Therapies**](https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html)**, 2019-2030.”**

The
report features an extensive study of the current market landscape, offering an
informed opinion on the likely adoption of these therapeutics over the next
decade. It features an in-depth analysis, highlighting the capabilities of
various stakeholders engaged in this domain. In addition to other elements, the
study includes:

·       
A detailed assessment of the current market
landscape of developers engaged in the development of neoantigen targeted
therapies.

·       
Detailed profiles of developers of neoantigen
targeted therapies (shortlisted on the basis of the number of pipeline
products).

·       
A detailed publication analysis of close to
300 peer-reviewed, scientific articles published during the period 2015-2019
(till February), highlighting the research focus within the industry.

·       
An in-depth analysis of the various patents
that have been filed / granted related to neoantigens.

·       
An analysis of the various partnerships pertaining
to neoantigen targeting therapies.

·       
An analysis of the investments made at
various stages of development in companies that are focused on developing
neoantigen targeted therapies.

For
more information, please visit [**https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html**](https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html)** **

A
detailed market forecast, featuring analysis of the current and projected
future opportunity across key market segments (listed below)

Target
Disease Indication

·       
Bone and Cartilage Cancer

·       
Colorectal Cancer

·       
Head and Neck Cancer

·       
Renal Carcinoma

·       
Hepatocellular Carcinoma

·       
Lung Cancer

·       
Gynecological Cancer

·       
Others

Type
of Treatment

·       
Personalized

·       
Off-the-shelf

Type
of Immunotherapy

·       
Dendritic Cell Vaccine

·       
DNA / RNA-based Vaccine

·       
Protein / Peptide-based Vaccine

·       
TIL-based Therapy

Route
of Administration

·       
Intradermal

·       
Intravenous

·       
Subcutaneous

·       
Others

Key
Geographical Region

·       
North America (US)

·       
Europe (UK, Germany, France, Italy, and Spain

·       
Rest of the World

Transcripts
of interviews held with the following senior level representatives of
stakeholder companies:

·       
Gabriel Nistor, Chief Scientific Officer,
AIVITA Biomedical

·       
Ella Sorani, Vice President Research and
Development, BioLineRx

·       
Heinz Lubenau, Chief Operating Officer and
Co-Founder, VAXIMM

Key
companies covered in the report

·       
Bavarian Nordic

·       
Genocea Biosciences

·       
Gradalis

·       
Immunicum

·       
Immunovative Therapies

·       
Iovance Biotherapeutics

·       
Medigene

·       
Neon Therapeutics

·       
Precision Biologics

·       
Vaxon Biotech

For
more information, please click on the following link:

[**https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html**](https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html)**    **

Chapter
Outlines

Chapter
2 provides
an executive summary of the insights captured in our research. It offers a
high-level view on the state of the market for neoantigen targeted therapies,
in the short-mid term and long term.

Chapter 3 provides a general overview of neoantigen
targeted therapies, featuring brief descriptions of the various conventional
forms of therapy that are used for the treatment of oncological disorders. It
also includes a discussion on the advent and evolution of cancer immunotherapy,
while highlighting its limitations. The chapter lays emphasis on the role of
neoantigens in cancer immunotherapy, providing details on the various types of
neoantigens, product development-related aspects of neoantigen targeted
therapies and the diverse strategies that are available / being investigated
for delivery of neoantigen-based therapeutics.

Chapter
4 includes
information on nearly 150 molecules that are currently under development for
the treatment of various cancer indications. It features a comprehensive
analysis of pipeline molecules, highlighting phase of development (marketed,
clinical and preclinical / discovery stage) of lead candidates, type of
molecule (small molecule and biologic), type of treatment (personalized and
off-the-shelf), type of therapy (monotherapy and combination therapy), type of
immunotherapy, target indication, line of treatment, and route of
administration of the drugs / therapies that are being developed for the
treatment of cancer. In addition, the chapter provides information on drug
developer(s), highlighting year of their establishment, location of headquarters
and employee strength.****

Chapter
5 provides
detailed profiles of some of the leading stakeholders in this field
(shortlisted on the basis of number of pipeline products). Each profile
presents a brief overview of the company, its financial information (if available),
product portfolio, recent collaborations and an informed future outlook.****

Chapter
6 provides
a detailed analysis of close to 300 research articles related to neoantigen
targeted therapies, published in the period 2015-2019 (till February). The analysis
takes into consideration several aspects, namely target disease indications,
affiliated cancer immunotherapies, and analysis based on various relevant
parameters, such as study type (review article, research article and
meta-analysis), year of publication, and most popular journals (in terms of
number of articles published in the given time period), within this domain.****

About
Roots Analysis

Roots
Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com

Contact
Information

Roots
Analysis Private Limited

Gaurav
Chaudhary

+1
(415) 800 3415

**Gaurav.Chaudhary@rootsanalysis.com**